Insights, Innovation and Impact
This timely update provides insights into health care sector stock performance and social impact themes related to U.N. Sustainable Development Goal 3 (Good Health and Well-Being).
September was a difficult month for equities, as rising interest rates and various uncertainties weighed on markets. Economic growth estimates worldwide were revised down to reflect apparent slowdowns in the U.S. and Chinese economies. Meanwhile, inflation rose, and the U.S. Federal Reserve appeared to lay the groundwork for cutting back its bond holdings and raising short-term interest rates in 2022. Investors faced additional uncertainty from the default of China’s largest real estate developer, Evergrande Holdings, and political grandstanding in Washington about raising the federal debt limit. Against this backdrop, non-U.S. developed market equities generally outperformed U.S., small-company stocks beat large and value outperformed growth.
Peaks in the rates of new COVID-19 cases and deaths came in mid- to late-August and declined in September, according to World Health Organization data.
We think it’s also important to mark significant progress in treating diabetes, a disease that afflicts more than 450 million people worldwide
Insulet is an innovative company that specializes in diabetes treatment. The company’s disposable, wearable patch pumps provide automated, continuous delivery of insulin.
Investment return and principal value of security investments will fluctuate. The value at the time of redemption may be more or less than the original cost. Past performance is no guarantee of future results.
The opinions expressed are those of American Century Investments (or the portfolio manager) and are no guarantee of the future performance of any American Century Investments' portfolio. This material has been prepared for educational purposes only. It is not intended to provide, and should not be relied upon for, investment, accounting, legal or tax advice.
References to specific securities are for illustrative purposes only, and are not intended as recommendations to purchase or sell securities. Opinions and estimates offered constitute our judgment and, along with other portfolio data, are subject to change without notice.